BOPA will take a stand on the healthcare issues that affect oncology pharmacy and cancer patients. Our position statements are there to promote the best interests of our members. They are independently produced by the committee in consultation with our members.
Biosimilar MABs Implementation Guidance February 2017This document describes the evidence, recommendations and practical considerations for adoption of biosimilar MABs. It also contains BOPA's position statement on biosimilar monoclonal antibodies used in oncology.
Biosimilar Monoclonal Antibody Position Statement (Feb 2017)The British Oncology Pharmacy Association’s (BOPA) position is that biosimilar monoclonal antibodies (MABs) are therapeutically equivalent to the originator molecules and can and should be used for all commissioned indications, provided pharmacovigilance safeguards are in place, e.g. branded prescribing. BOPA’s full position statement, which should be read in conjunction with BOPA's implimentation guidelines is below.